Fig. 6: BCL9 knockout, and propranolol treatment reduces CRC progression and stromal cell infiltration in vivo.

Top: a Tumor burden assessed by body live imaging over time. Each dot represents mean; error bars, standard error of the mean. P values were calculated using Student’s t test. *P < 0.05. n = 7 for both groups. Day 0 indicates first measurement. b Top: body live images taken on day 34. Bottom: representative histology and BCL9 immunostain of xenograft tumors. Arrowheads indicates accumulation of BCL9 around paraspeckles. Scale bars: black 50 μm; white, 20 μm. c Representative immunohistochemical analysis of xenograft tumors. Scale bars: white, 20 μm; black, 50 μm. d Percentage of β-catenin (left) and Ki-67 (right) positive cells per ROI. N: number of ROIs analyzed. Tumor nodules dissected from three mice implanted with wild-type or BCL9 knockout RKO cells were used for analysis. Crosses represent mean and standard deviation. P values were calculated using Welch’s t test. ****P < 0.0001. e Percentage of the area positive for CD163, CD31, and αSMA staining per region of interest (ROI). P values were calculated using Student’s t test. ****P < 0.0001. n.s.: not significant. Bottom: f Tumor burden assessed by body live imaging over time. Each dot represents mean; error bars, standard error of the mean fold change. P values were calculated using Student’s t test. n = 7 for both groups. ****P < 0.0001. Day 1 indicates first measurement. g Body live images taken on days 1, 7, 14, and 21. h Percentage of indicated cells of per ROI. N: number of ROIs analyzed. P values were calculated using Student’s t test **P < 0.01. ***P < 0.001. n.s.: not significant. i Representative immunohistochemical analysis of xenograft tumors. Scale bars: 50 μm. Data are displayed as mean ± SD.